Organization
Alentis Therapeutics
3 clinical trials
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive GlomerulonephritisStatus: Recruiting, Estimated PCD: 2025-09-25
Clinical trial
A Double-Blind Placebo-Controlled Randomised Phase 1b Study of the Pharmacokinetics of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild CirrhosisStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2028-02-01